May 4, 2005 -- Renovis and AstraZeneca reported partial success for a stroke-treating drug called Cerovive. The compound is designed to trap free radicals that occur after an ischemic stroke, which comprise 85% of all strokes. The news had a huge effect on Renovis stock, which almost doubled. We look at the conflicting data and assess the prospects for Renovis...
